Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, 310006, China.
Research Centre for Analytical Instrumentation, Institute of Cyber-Systems and Control, State Key Laboratory of Industrial Control Technology, Zhejiang University, Hangzhou, Zhejiang Province, 310027, China.
Biosens Bioelectron. 2022 Dec 1;217:114715. doi: 10.1016/j.bios.2022.114715. Epub 2022 Sep 14.
Liquid biopsies have piqued the interest of researchers as a new tumor diagnosis technique due to their unique benefits of non-invasiveness, sensitivity, and convenience. Recent advances in microfluidic technology have integrated separation, purification, and detection, allowing for high-throughput, high-sensitivity, and high-controllability detection of specific biomarkers in liquid biopsies. With the increasing demand for tumor detection and individualized treatment, new challenges are emerging for the ever-improving microfluidic technology. The state-of-the-art microfluidic design and fabrications have been reviewed in this manuscript, and how this technology can be applied to liquid biopsies from the point of view of the detection process. The primary discussion objectives are circulating tumor cells (CTCs), exosomes, and circulating nucleic acid (ctDNA). Furthermore, the challenges and future direction of microfluidic technology in detecting liquid biomarkers have been discussed.
液体活检作为一种新的肿瘤诊断技术,因其具有非侵入性、敏感性和便利性等独特优势,引起了研究人员的兴趣。微流控技术的最新进展将分离、纯化和检测集成在一起,使得液体活检中特定生物标志物的高通量、高灵敏度和高可控性检测成为可能。随着肿瘤检测和个体化治疗需求的增加,微流控技术不断改进,也出现了新的挑战。本文综述了最先进的微流控设计和制造技术,并从检测过程的角度讨论了该技术如何应用于液体活检。主要讨论的对象是循环肿瘤细胞(CTC)、外泌体和循环核酸(ctDNA)。此外,还讨论了微流控技术在检测液体生物标志物方面的挑战和未来方向。